Liao Guiping, Zhou Yali, Yin Xiaolin, He Sheng, Wu Yi, Xiao Jian, Geng Zhili, Huang Qiuying, Luo Ganghui, Yang Kun
Department of Hematology, The 923 Hospital of the Joint Logistics Support Force of the People's Liberation Army, Nanning, China.
Department of Genetic and Metabolic Laboratory, Guangxi Zhuang Autonomous Region Women and Children Health Care Hospital, Nanning, China.
Mediterr J Hematol Infect Dis. 2022 May 1;14(1):e2022034. doi: 10.4084/MJHID.2022.034. eCollection 2022.
IVS-II-5 G>C () is a rare β-thalassemia mutation. However, there is no clear evidence regarding the effect of this defect or co-inheritance of other β-thalassemia mutations on phenotypes.
The clinical phenotypes associated with compound heterozygosity for the IVS-II-5 G>C mutation and other β-thalassemia mutations, together with the genetic modifiers' potential effect of the genetic modifiers α-thalassemia, were studied in 13 patients. In addition, analyses of red cell indices, hemoglobin component, iron status, and α-globin genes were carried out in 19 heterozygotes.
Next-generation sequencing of 24 undiagnosed patients with transfusion-dependent thalassemia (TDT) or non-transfusion-dependent thalassemia (NTDT) identified 13 carriers of the IVS-II-5 G>C mutation. There was a wide spectrum of phenotypic severity in compound heterozygotes and 6 (46.2%) of 13 were transfusion dependent. Analysis of 19 heterozygotes indicated that most were hematologically normal without appreciable microcytosis or hypochromia, and approximately half had normal hemoglobin A levels at the same time.
Compound heterozygotes for IVS-II-5 G>C and other severe β-thalassemia mutations are phenotypically severe enough to necessitate appropriate therapy and counselling. Co-inheritance of this nucleotide substitution with other β-thalassemia mutations may account for a considerable portion of the incidence of undiagnosed patients with NTDT and TDT in Guangxi. Therefore, the IVS-II-5 G>C mutation can pose serious difficulties in screening and counselling.
IVS-II-5 G>C()是一种罕见的β地中海贫血突变。然而,关于这种缺陷或其他β地中海贫血突变的共同遗传对表型的影响,尚无明确证据。
研究了13例患者中与IVS-II-5 G>C突变及其他β地中海贫血突变的复合杂合性相关的临床表型,以及遗传修饰因子α地中海贫血的潜在影响。此外,对19例杂合子进行了红细胞指数、血红蛋白成分、铁状态和α珠蛋白基因分析。
对24例未确诊的输血依赖型地中海贫血(TDT)或非输血依赖型地中海贫血(NTDT)患者进行二代测序,发现13例IVS-II-5 G>C突变携带者。复合杂合子的表型严重程度范围广泛,13例中有6例(46.2%)依赖输血。对19例杂合子的分析表明,大多数患者血液学正常,无明显的小红细胞症或低色素血症,约一半患者同时血红蛋白A水平正常。
IVS-II-5 G>C与其他严重β地中海贫血突变的复合杂合子表型严重,需要进行适当的治疗和咨询。这种核苷酸替代与其他β地中海贫血突变的共同遗传可能占广西未确诊NTDT和TDT患者发病率的相当一部分。因此,IVS-II-5 G>C突变在筛查和咨询中可能带来严重困难。